Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 20, 2022

BUY
$0.13 - $12.4 $20,162 - $1.92 Million
155,095 Added 23.77%
807,535 $566,000
Q2 2022

Jul 26, 2022

BUY
$1.11 - $3.46 $724,208 - $2.26 Million
652,440 New
652,440 $946,000
Q1 2022

Apr 25, 2022

SELL
$1.78 - $8.5 $1.48 Million - $7.08 Million
-832,555 Closed
0 $0
Q4 2021

Jan 19, 2022

BUY
$7.3 - $11.24 $6.08 Million - $9.36 Million
832,555 New
832,555 $6.5 Million

Others Institutions Holding SABS

About SAB Biotherapeutics, Inc.


  • Ticker SABS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,030,900
  • Market Cap $111M
  • Description
  • SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...
More about SABS
Track This Portfolio

Track First Premier Bank Portfolio

Follow First Premier Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Premier Bank, based on Form 13F filings with the SEC.

News

Stay updated on First Premier Bank with notifications on news.